Shenandoah
Shenandoah
The valley between mountain ranges. Quiet, deep, agricultural. Where the land has been tended carefully for a very long time and everything that grows here benefits from what the soil already knows.
Immune balance that starts in the gut.
The organism that trains and regulates the immune system.
Rich and creamy. A clean, mild flavor. Our everyday classic.
Richer, with a deeper and more complex flavor. For those who want more from every jar.
Our richest and thickest. Cold-strained for maximum culture concentration.
Produced in a home kitchen under the Wyoming Food Freedom Act - not inspected by the state or a local health department. For informed consumers only.
*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Breast milk evolved to contain sugars that feed this organism, not the infant.
Human breast milk contains between 150 and 200 distinct oligosaccharide structures — complex sugars that the infant cannot digest. There is no enzyme in the human digestive system that breaks them down. For decades, researchers were puzzled by why so much energy goes into producing sugars a baby cannot use.
The answer is that they are not for the baby. They are for Bifidobacterium infantis. B. infantis carries a unique, highly specialized gene cluster — the HMO utilization cluster — that encodes every enzyme needed to break down and ferment all classes of human milk oligosaccharides. No other Bifidobacterium species has the complete set. Breast milk evolved to contain HMOs specifically because of B. infantis.
This is one of the most elegant co-evolutionary relationships in human biology: a mother produces complex sugars at significant metabolic cost, in her milk, specifically to nourish a bacterium that in turn produces the compounds — butyrate, acetate, and immune-educating signals — that protect and develop her infant's gut and immune system. The infant benefits from what B. infantis produces. The mother invests in the organism, not directly in the infant.
In adults, B. infantis does not require HMOs — it ferments complex plant polysaccharides through related enzymatic pathways. But its immune-educating mechanisms continue to operate throughout the human lifespan. Shenandoah delivers B. infantis to adults who — for reasons specific to modern Western life — have largely lost it.
"The human infant gut microbiome is not random colonization. It is a curated ecosystem, seeded through breast milk and birth canal transmission, designed to establish specific organisms — led by B. infantis — whose metabolic and immune-educating activities are precisely what the developing gut requires."
B. infantis has nearly disappeared from Western populations in one century.
Breastfed infants in non-industrialized countries have gut microbiomes dominated by B. infantis — comprising 70 to 90 percent of total gut bacteria. Breastfed infants in industrialized Western nations frequently carry little to none. The same organism. The same food. Dramatically different colonization.
This is not a gradual evolutionary change. It happened within roughly four generations — since widespread antibiotics, hospital birth practices that disrupt maternal microbiome transmission, formula supplementation, and dietary shifts eliminated fermented food consumption. The transmission chain that established B. infantis in each generation was broken, and has not recovered.
Antibiotics given to mothers during labor — administered in approximately 30 to 40 percent of U.S. births — dramatically reduce the maternal B. infantis populations that would otherwise be transmitted to the infant. A mother cannot transmit what she does not carry. Each antibiotic-affected birth represents a potential break in the generational transmission chain.
B. infantis requires HMOs as its preferred substrate in the infant gut. Formula does not contain HMOs. Infants supplemented with formula — even partially — have significantly lower B. infantis colonization than exclusively breastfed infants, because the organism's primary substrate is absent.
Bifidobacterium species are among the most antibiotic-sensitive gut organisms. Adult B. infantis populations — already lower than historical baselines — are further depleted by each antibiotic course. Recovery requires deliberate re-introduction rather than passive recovery from environmental exposure.
In adults, B. infantis ferments complex plant polysaccharides. The Western diet provides minimal substrate. Without adequate complex carbohydrate substrate, B. infantis populations cannot maintain density even when present — creating a substrate-depletion cycle that mirrors the HMO shortage in formula-fed infants.
How B. infantis feeds the gut and teaches the immune system.
Four mechanisms — two affecting the gut lining directly, two affecting the immune system in ways that extend far beyond digestion.
B. infantis ferments complex carbohydrates — HMOs in infants, diverse plant polysaccharides in adults — into short-chain fatty acids, primarily butyrate and acetate. Butyrate is the primary energy source for colonocytes — the epithelial cells lining the colon. Approximately 70 percent of colonocyte energy derives from butyrate. Well-fueled colonocytes maintain tighter junctions, produce more protective mucin, and have better structural integrity. B. infantis's contribution to the gut barrier is energetic rather than signaling-based — it feeds the cells that build and maintain the wall.
Fecal calprotectin is a protein released by neutrophils during gut inflammation — the standard clinical marker for intestinal inflammatory activity. Multiple independent studies have found that B. infantis supplementation reduces fecal calprotectin levels, even in people without diagnosed inflammatory conditions. This reduction indicates less active immune activation in the gut — a quieter, less reactive intestinal immune state associated with better gut comfort and lower systemic inflammatory load.
B. infantis is one of the most potent inducers of regulatory T cells (Tregs) among probiotic organisms. Tregs are the immune system's tolerance mechanism — they suppress inappropriate immune responses against harmless antigens (food, commensal bacteria, self-tissue) while preserving capacity to respond to genuine threats. B. infantis does this through signaling to gut dendritic cells, which promote Treg differentiation rather than inflammatory T helper cell activation. This immune education continues operating in adults through the same mechanism established in infancy.
B. infantis strongly stimulates IL-10 production — the immune system's primary anti-inflammatory cytokine. IL-10 counterbalances pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) that drive chronic inflammation. B. infantis normalization of the IL-10/IL-12 ratio — documented in human trials — shifts the immune environment toward a more balanced, tolerant state. This systemic effect is why B. infantis's documented benefits extend beyond digestive health into inflammatory conditions including psoriasis and chronic fatigue syndrome.
Published research. Read it yourself.
Four studies — including two that document B. infantis's effects outside the gut entirely, which is among the strongest evidence for systemic rather than local-only probiotic action.
Read the detail
Three parallel RCTs examining B. infantis 35624's effects on inflammatory markers in IBS patients, psoriasis patients, and CFS/ME patients. All three conditions involve elevated systemic inflammatory markers despite having no common clinical presentation. The study tested whether B. infantis could modulate systemic inflammation across conditions with different tissue targets.
B. infantis 35624 significantly reduced CRP, TNF-alpha, and other inflammatory markers in all three populations simultaneously — in a gut condition, a skin condition, and a neurological condition. The finding that a gut probiotic reduces inflammation in psoriasis and CFS/ME confirms that B. infantis's anti-inflammatory effects are systemic rather than limited to the digestive system, operating through the IL-10 and immune regulatory pathways documented in earlier mechanistic work.
Read the detail
An RCT in 75 IBS patients comparing B. infantis 35624 versus L. salivarius versus placebo. Beyond symptom measurement, the study specifically measured the IL-10/IL-12 cytokine ratio — a marker of immune balance where higher IL-10 relative to IL-12 indicates a more tolerant immune state. IBS patients typically show an abnormally low IL-10/IL-12 ratio compared to healthy controls.
B. infantis supplementation normalized the IL-10/IL-12 ratio toward the ratio seen in healthy controls, alongside significant improvements in abdominal pain, bloating, and overall satisfaction. L. salivarius produced neither the immune normalization nor the symptom improvement. This was the first direct demonstration in a human RCT that a probiotic could normalize an abnormal immune cytokine ratio — suggesting B. infantis's immune effects were corrective rather than merely additive.
Read the detail
A genomic and fermentation study characterizing the HMO utilization capacity of B. infantis and other Bifidobacterium species. Researchers identified the HMO utilization gene cluster, tested fermentation capacity across all major HMO classes, and compared B. infantis with other species.
B. infantis was the only Bifidobacterium species with the complete HMO utilization gene cluster — encoding all enzymes necessary to metabolize all major HMO classes. When grown on HMOs as the sole carbon source, B. infantis outcompeted all other tested organisms. The study established the molecular basis for the co-evolutionary relationship between B. infantis and human breast milk: the genome is shaped specifically for this food source, and the food source appears shaped specifically for this genome.
Read the detail
A comparative study examining B. infantis colonization rates in breastfed infants across industrialized Western populations versus non-industrialized populations, characterizing the mechanisms driving the difference: antibiotic exposure, birth practices, formula supplementation, and maternal microbiome composition.
B. infantis was detected in the vast majority of breastfed infants in non-industrialized populations but in a small minority of breastfed North American and Western European infants — despite the same food source. The difference correlated strongly with intrapartum antibiotic use, C-section delivery rates, and formula supplementation, all of which disrupt the maternal-to-infant transmission chain. The study established that B. infantis absence in Western infants is a recent industrialization-driven disruption, not a normal variation.
Note: PubMed links use search queries rather than direct DOIs. Identify the correct paper by author, journal, and year. Vital Yogurts is not affiliated with any research institutions cited.
Honest about what to expect.
Shenandoah is the culture whose most significant effects are the ones you won't feel directly. The immune education and systemic anti-inflammatory effects build over months. What you notice is gentler but real.
-
1
Reduced gut reactivity over weeks
The fecal calprotectin data shows B. infantis reduces active gut inflammation. Most people don't measure their calprotectin — but they notice what reduced gut inflammation feels like: foods that previously caused discomfort become more tolerable, the gut feels less reactive day to day, and the baseline of comfort rises gradually. This typically develops over three to six weeks of consistent use.
-
2
Gentle, consistent digestive ease
Butyrate production is the most direct mechanism for colonocyte health. Well-fueled colonocytes maintain better barrier integrity, produce more mucin, and create a more stable gut environment. People who use Shenandoah consistently describe a gut that feels more settled — not dramatically improved in any single week, but noticeably more consistent over months.
-
3
Systemic effects that show in other ways
The Groeger trial documented B. infantis's anti-inflammatory effects in psoriasis patients and CFS/ME patients — not just IBS patients. People who carry chronic low-grade inflammation that manifests in joint discomfort, skin reactivity, or energy irregularity sometimes notice these symptoms improving with consistent Shenandoah use over two to three months. This is the systemic IL-10 mechanism operating beyond the gut.
-
4
The long-term investment you cannot feel working
Immune education through Treg development is a long-arc process. The reduction in inappropriate immune reactivity that B. infantis supports — less autoimmune tendency, better tolerance of commensal bacteria, more precise immune discrimination — shows over years of consistent use. This is the reason to keep using Shenandoah long after the digestive benefits have become the new normal. The most important work it does produces no felt experience at all.
Our Live Fermented Milks are genuinely potent. When you introduce a large number of live beneficial cultures into a microbiome that has grown quieter over time, your body notices. Some people feel temporary bloating or mild discomfort in the first hour or two after their first few servings. This is your body adjusting. It passes. Start with two to four ounces and pay attention to how you feel before adding more. The daily ritual builds over weeks, not hours.
Cultures that complement Shenandoah.
Shenandoah provides colonocyte fuel and immune education. These three cultures add structural barrier support, immune defense activation, and gut stability during disruption.
Structural gut barrier support through tight junction protein signaling. Works alongside Shenandoah's colonocyte fuel — building the barrier from two directions.
Hudson Valley Lactobacillus acidophilusSecretory IgA induction complements Shenandoah's Treg development — together covering both arms of mucosal immune support.
Cascade Bacillus subtilisVitamin K2 production and pathogen exclusion. The most resilient culture in the line — a natural long-term pairing with Shenandoah's foundational immune work.